{"id":"pegylated-rhg-csf-regimen","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Splenomegaly"},{"rate":"5-10","effect":"Elevated uric acid"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils. Pegylation extends the drug's half-life by reducing renal clearance and increasing circulation time, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of neutrophil counts, reducing infection risk in patients with chemotherapy-induced neutropenia or other causes of low neutrophil counts.","oneSentence":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:23:26.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN)"},{"name":"Severe congenital neutropenia"},{"name":"Idiopathic or cyclic neutropenia"}]},"trialDetails":[{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT06926751","phase":"PHASE2","title":"Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-07","conditions":"Solid Tumors, Children, Adolescent","enrollment":132},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05536154","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-11-01","conditions":"Lymphoma, Multiple Myeloma","enrollment":68},{"nctId":"NCT05510089","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies","status":"UNKNOWN","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-09-01","conditions":"Hematological Malignancy","enrollment":62},{"nctId":"NCT04477616","phase":"PHASE2","title":"Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-07-13","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT05222009","phase":"PHASE1","title":"G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor","enrollment":25},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04497688","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-01-01","conditions":"Non Hodgkin's Lymphoma","enrollment":104},{"nctId":"NCT04497701","phase":"NA","title":"Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Lymphoma, Leukemia","enrollment":139},{"nctId":"NCT03731442","phase":"PHASE3","title":"Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-11-01","conditions":"Esophageal Cancer","enrollment":300},{"nctId":"NCT02996617","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2016-11","conditions":"Lymphoma,Non-Hodgkin","enrollment":240},{"nctId":"NCT01611051","phase":"PHASE3","title":"A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-03","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":330},{"nctId":"NCT01560195","phase":"PHASE3","title":"A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-04","conditions":"NSCLC, Neutropenia, Febrile Neutropenia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pegylated rhG-CSF regimen","genericName":"Pegylated rhG-CSF regimen","companyName":"Shandong Provincial Hospital","companyId":"shandong-provincial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}